Injectable Drug Delivery Devices Market Trends

ID: MRFR/MED/0704-CR

164 Pages

Rahul Gotadki

August 2019

Injectable drug delivery Market Research Report Information by Devices (Conventional Injection Devices, Self-Injection Devices), By Therapeutic Application (Autoimmune Diseases, Hormonal Disorders and Cancer) By Usage Pattern (Curative pattern, Immunization), By Site of Delivery (Intramuscular, Subcutaneous, Intra Dermal), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2035

Injectable Drug Delivery Devices Market Infographic

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Trends

Introduction

In 2024, the Injectable Drugs Market is experiencing a great transformation, driven by a confluence of macroeconomic factors. Technological advancements, especially in the area of device design and formulation science, are enhancing the efficacy and patient compliance of injectable therapies. At the same time, regulatory pressures are changing, putting greater emphasis on patient safety and innovation, and thereby influencing product development and approval time. Meanwhile, changes in patient behavior, such as a growing preference for self-medication and home health solutions, are also changing the market’s dynamics. These trends are strategically important to market participants, as they not only influence their competitive positioning, but also guide their investment and product development strategies in an increasingly complex healthcare landscape.

Top Trends

Increased Adoption of Biologics
The growth in biotech drugs has resulted in an increased demand for injectable drug delivery systems, with over 50% of new drugs in 2023 being biotech. Consequently, companies like Johnson & Johnson are investing heavily in this area to strengthen their product lines. In the process, they are also developing new drug delivery systems, which should lead to improved patient outcomes. As the delivery of biotech drugs often requires more complex devices, the market will also see a shift towards more sophisticated devices. In the future, smart drug delivery systems that monitor patient compliance are expected to emerge.
Integration of Digital Health Technologies
The injection of the drug in the body has been replaced by the injection of the digital data. Companies like Eli Lilly are developing connected devices that can monitor adherence to a treatment. A study showed that digital health solutions can improve adherence to treatment by as much as 30 per cent. This trend will engage the patient and provide real-time data to the healthcare system. The feedback from the digital data will help in developing a personalised treatment plan.
Focus on Patient-Centric Designs
The injection drug industry is increasingly focusing on patient-centered design, and companies like Becton, Dickinson and Company are leading the way. According to their research, about 70 percent of patients prefer devices that are easy to use and minimize pain. The result is a trend toward patient-friendly devices that can increase patient compliance. Future developments may include devices that can be adapted to individual needs.
Regulatory Support for Advanced Delivery Systems
Regulators are increasingly encouraging the development of new injection systems, as is evidenced by the FDA’s accelerated approval processes for innovative devices. This support is vital for companies like Antares, which are developing new delivery systems. It is hoped that this trend will help to speed up the time to market for new medicines, which will benefit both manufacturers and patients. In the future, it is hoped that regulators will further simplify the approval process for complex delivery systems.
Emergence of Biosimilars
The rise of biosimilars is reshaping the injectable drug delivery market, and major companies such as Novartis AG are entering this market. Biosimilars can reduce the cost of treatment by up to 30 percent, making it more affordable for patients. This trend is resulting in fierce competition and innovation in drug delivery systems as companies try to differentiate their products. Future drug delivery systems may be designed specifically for biosimilars.
Sustainability in Packaging and Delivery
The injectable drug market is now focusing on sustainability, with companies such as AstraZeneca introducing eco-friendly packaging. The latest studies show that 60% of consumers prefer products with sustainable packaging. This trend is driving manufacturers to adopt a greener approach, which in turn can increase brand loyalty. In the future, the use of sustainable materials may be subject to tighter regulations and the demand for sustainable drug delivery systems is likely to increase.
Advancements in Needle-Free Delivery Systems
Needle-free injections are gaining ground, with innovations from companies such as Hoffmann-La Roche AG. It has been proven that needle-free injections can reduce needlestick injuries by up to 80 per cent. This trend will increase the market for injectables, especially in the paediatric and elderly populations. Needle-free injections will also be used for products such as vaccines. The future of needle-free injections lies in improving the effectiveness and scope of these products.
Personalized Medicine and Tailored Delivery Solutions
A rethinking of drug delivery systems is now taking place in the direction of a more individual medicine. Mylan N.V., for example, is developing a range of injection systems that can be adapted to individual needs. And in the study of individual treatment, a clinical success rate of up to 25 per cent has been calculated. This trend is accompanied by a need for flexible delivery systems that can be adapted to different dosages and administration routes. Moreover, future developments may include sophisticated dose-calculation methods based on individual data.
Growth of Home Healthcare Solutions
Home care has become an important area of interest. Among the companies which are developing injectables for home use is Eisai Co., Ltd. The company’s research shows that 40% of patients prefer to be treated at home. This trend could result in a reduction of medical costs and increased satisfaction for the patients. In the future, home use devices will be equipped with a remote control system.
Collaboration and Partnerships in Innovation
The collaboration between pharmaceutical companies and technical companies is advancing injectable drug delivery. This is the case with AstraZeneca and its partners in the start-up industry. This trend is making the market more competitive and advancing the field rapidly. The future may see more cross-industry collaborations addressing complex health issues.

Conclusion: Navigating the Injectable Drug Delivery Landscape

In 2024 the injectable drug delivery market will be characterized by an intensely competitive and highly fragmented environment, with both legacy and new players competing for a larger share of the market. The regional trends indicate an increased demand for innovation in injectable drug delivery systems, particularly in North America and Asia-Pacific, where the regulatory environment is becoming increasingly favourable. The companies are now deploying a range of advanced capabilities, such as artificial intelligence for the provision of individualized medicine, automation for improved efficiency, and sustainable initiatives to meet evolving customer expectations. Also critical to success will be the flexibility of the product portfolio, as market needs evolve. These developments will need to be taken into account in the investment priorities of companies seeking to establish leadership and gain a competitive edge.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the projected market valuation of The Global Injectable Drug Delivery by 2035?

The projected market valuation for The Global Injectable Drug Delivery by 2035 is 268.23 USD Billion.

What was the market valuation of The Global Injectable Drug Delivery in 2024?

The overall market valuation of The Global Injectable Drug Delivery was 124.69 USD Billion in 2024.

What is the expected CAGR for The Global Injectable Drug Delivery during the forecast period 2025 - 2035?

The expected CAGR for The Global Injectable Drug Delivery during the forecast period 2025 - 2035 is 7.21%.

Which companies are considered key players in The Global Injectable Drug Delivery?

Key players in The Global Injectable Drug Delivery include AbbVie, Bristol-Myers Squibb, Pfizer, Roche, Sanofi, Merck & Co., Amgen, Johnson & Johnson, and Novartis.

What are the projected values for Conventional Injection Devices and Self-Injection Devices by 2035?

By 2035, the projected value for Conventional Injection Devices is 158.23 USD Billion, while Self-Injection Devices is expected to reach 110.0 USD Billion.

How do the therapeutic applications of Autoimmune Diseases and Hormonal Disorders and Cancer compare in market valuation by 2035?

By 2035, the market valuation for Autoimmune Diseases is projected to be 81.12 USD Billion, whereas Hormonal Disorders and Cancer is expected to reach 187.11 USD Billion.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per MRFR analysis, The Global Injectable Drug Delivery was estimated at 124.69 USD Billion in 2024. The market is projected to grow from 133.68 USD Billion in 2025 to 268.23 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.21 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Global Injectable Drug Delivery is poised for substantial growth driven by technological advancements and increasing demand for biologics.

North America remains the largest market for injectable drug delivery, driven by advanced healthcare infrastructure and high adoption rates. The Asia-Pacific region is emerging as the fastest-growing market, fueled by increasing investments in healthcare and rising patient populations. Conventional injection devices dominate the market, while self-injection devices are experiencing rapid growth due to their convenience and patient preference. Technological innovations in drug delivery systems and the rising prevalence of chronic diseases are key drivers propelling market expansion.

Injectable Drug Delivery Devices Market

CAGR

7.21%

Market Size & Forecast

2024 Market Size	124.69 (USD Billion)
2035 Market Size	268.23 (USD Billion)
CAGR (2025 - 2035)	7.21%
Largest Regional Market Share in 2024	North America

Major Players

AbbVie (US), Bristol-Myers Squibb (US), Pfizer (US), Roche (CH), Sanofi (FR), Merck & Co. (US), Amgen (US), Johnson & Johnson (US), Novartis (CH)

Market Trends

The Global Injectable Drug Delivery is currently experiencing a transformative phase, characterized by advancements in technology and increasing demand for efficient drug administration methods. This market encompasses a wide array of products, including prefilled syringes, auto-injectors, and wearable injectors, which are gaining traction due to their convenience and ease of use. The rise in chronic diseases and the need for biologics are driving the adoption of injectable solutions, as they offer rapid absorption and targeted delivery. Furthermore, the integration of smart technologies into these devices is enhancing patient compliance and monitoring, thereby improving therapeutic outcomes. In addition to technological innovations, The Global Injectable Drug Delivery is influenced by regulatory frameworks that are evolving to accommodate new delivery systems. Manufacturers are focusing on developing user-friendly devices that cater to the needs of patients and healthcare providers alike. The emphasis on personalized medicine is also shaping the landscape, as tailored therapies require precise delivery mechanisms. As the market continues to expand, collaboration between pharmaceutical companies and technology firms is likely to foster further innovations, ensuring that the sector remains dynamic and responsive to emerging healthcare challenges.

Technological Advancements

The Global Injectable Drug Delivery is witnessing rapid technological advancements, particularly in device design and functionality. Innovations such as smart injectors and connected devices are enhancing user experience and adherence to treatment regimens. These developments not only improve the efficiency of drug delivery but also facilitate real-time monitoring of patient health.

Rising Demand for Biologics

There is a growing demand for biologics within The Global Injectable Drug Delivery, driven by the increasing prevalence of chronic diseases. Biologics often require injectable delivery methods due to their complex structures and the need for precise dosing. This trend is likely to continue as more biologic therapies are developed and approved.

Focus on Patient-Centric Solutions

The emphasis on patient-centric solutions is reshaping The Global Injectable Drug Delivery. Manufacturers are prioritizing the development of devices that enhance comfort and ease of use for patients. This focus on user experience is expected to drive market growth, as healthcare providers seek to improve patient compliance and satisfaction.

Injectable Drug Delivery Devices Market Market Drivers

Focus on Patient-Centric Solutions

The Global Injectable Drug Delivery Industry is increasingly oriented towards patient-centric solutions, emphasizing the need for convenience and ease of use in drug administration. Patients are seeking more accessible and user-friendly delivery methods, which has led to the development of pre-filled syringes and wearable injectors. These innovations not only enhance patient compliance but also improve the overall treatment experience. Market Research Future indicates that patient-centric devices are expected to capture a significant share of the market, with a projected growth rate of 10% annually. This shift towards patient-centricity is likely to drive manufacturers to invest in research and development, further propelling the injectable drug delivery market.

Increasing Prevalence of Chronic Diseases

The Global Injectable Drug Delivery Industry is significantly influenced by the rising prevalence of chronic diseases, including diabetes, cancer, and autoimmune disorders. As these conditions become more widespread, the demand for effective treatment options is escalating. Injectable therapies, particularly biologics and monoclonal antibodies, are increasingly being utilized due to their targeted action and rapid onset of effects. For instance, the market for injectable diabetes medications is projected to grow at a CAGR of 8% through 2027, reflecting the urgent need for effective management solutions. This trend suggests that the market will continue to expand as healthcare providers seek innovative delivery methods to address the growing burden of chronic illnesses.

Regulatory Support and Favorable Policies

The Global Injectable Drug Delivery Industry benefits from supportive regulatory frameworks and favorable policies that encourage innovation and market entry. Regulatory agencies are increasingly streamlining approval processes for new injectable therapies, which facilitates quicker access to the market. For instance, the introduction of expedited pathways for biologics and novel drug delivery systems has been instrumental in fostering growth. Additionally, government initiatives aimed at promoting healthcare access and affordability are likely to bolster the injectable drug delivery market. As these policies evolve, they may create a conducive environment for the development and commercialization of advanced injectable solutions, thereby enhancing market dynamics.

Rising Demand for Biologics and Biosimilars

The Global Injectable Drug Delivery Industry is witnessing a notable increase in the demand for biologics and biosimilars, which are often administered via injection. Biologics, including therapeutic proteins and monoclonal antibodies, are gaining traction due to their effectiveness in treating complex diseases. The biosimilars market is also expanding, driven by the need for cost-effective alternatives to expensive biologic therapies. It is estimated that the biosimilars market could reach USD 30 billion by 2025, indicating a robust growth trajectory. This rising demand is likely to propel the injectable drug delivery market, as manufacturers focus on developing advanced delivery systems that ensure optimal therapeutic outcomes.

Technological Innovations in Drug Delivery Systems

The Global Injectable Drug Delivery Industry is experiencing a surge in technological innovations that enhance the efficacy and safety of drug administration. Advanced delivery systems, such as smart syringes and auto-injectors, are being developed to improve patient compliance and reduce the risk of needle-stick injuries. These innovations are projected to drive market growth, with the market for auto-injectors alone expected to reach USD 50 billion by 2026. Furthermore, the integration of digital health technologies, such as mobile applications for monitoring and managing drug delivery, is likely to transform patient experiences. As these technologies evolve, they may lead to more personalized treatment regimens, thereby increasing the overall demand for injectable drug delivery solutions.

Market Segment Insights

By Device: Conventional Injection Devices (Largest) vs. Self-Injection Devices (Fastest-Growing)

In The Global Injectable Drug Delivery, Conventional Injection Devices hold the largest market share, primarily due to their established use in healthcare settings. This segment includes traditional syringes and autoinjectors, which continue to be the go-to choice for administering medications. Their reliability and ease of use have enabled them to maintain dominance amidst evolving technologies. Conversely, Self-Injection Devices are rapidly emerging as a significant growth segment within this market. Driven by the increasing demand for patient autonomy and home healthcare solutions, these devices are becoming essential for chronic disease management. The rise in health consciousness and the preference for less invasive methods are further boosting their popularity, indicating a promising future for this segment.

Technology: Conventional Injection Devices (Dominant) vs. Self-Injection Devices (Emerging)

Conventional Injection Devices are the staple of injectable drug delivery, favored for their simplicity and effectiveness. They are predominantly used in hospitals and clinics for various applications, including vaccinations and chronic disease therapies. The segment is characterized by a high level of familiarity among healthcare professionals and patients alike, which solidifies its position as the dominant choice. On the other hand, Self-Injection Devices are on the rise, attracting attention from both patients and healthcare providers. They allow patients to administer their medications at home, fostering independence and compliance. The increasing prevalence of chronic illnesses such as diabetes is propelling this segment forward, as self-injection devices offer an innovative solution to enhance patient engagement and treatment adherence.

By Therapeutic Application: Autoimmune Diseases (Largest) vs. Hormonal Disorders and Cancer (Fastest-Growing)

In The Global Injectable Drug Delivery, the therapeutic application segment is primarily dominated by <a href="https://www.marketresearchfuture.com/reports/autoimmune-disease-treatment-market-5586">autoimmune diseases</a>, which account for a significant share of market demand. This is largely due to the increasing prevalence of autoimmune disorders and the growing awareness regarding advanced treatment options available in injectable formulations. On the other hand, hormonal disorders and cancer represent a rapidly expanding segment, reflecting a heightened focus on targeted therapies and personalized medicine in oncology as well as endocrine disorders.

Therapeutic Applications: Autoimmune Diseases (Dominant) vs. Hormonal Disorders and Cancer (Emerging)

Autoimmune diseases have emerged as the dominant therapeutic application within the injectable drug delivery market, primarily attributed to chronic conditions that require ongoing management. The expanding market for these therapies is driven by the rising incidence of autoimmune disorders and continual advancements in biologics and monoclonal antibodies. Conversely, hormonal disorders and cancer signify the emerging applications in the space, fueled by innovations in targeted delivery systems that enhance efficacy and patient compliance. This segment is characterized by the incorporation of advanced drug formulations and is expected to see substantial growth as therapies evolve towards more sophisticated approaches.

By Usage Pattern: Curative Pattern (Largest) vs. Immunization (Fastest-Growing)

In The Global Injectable Drug Delivery, the Usage Pattern segment is predominantly characterized by the Curative Pattern, holding the largest share due to its established application in treating various health conditions. The Curative Pattern encompasses a wide range of therapeutics, catering to chronic diseases, which significantly contributes to its robust market presence. On the other hand, the Immunization segment, though currently smaller, is rapidly expanding as vaccination programs become more prevalent worldwide, driving growth in preventive healthcare initiatives.

Usage Patterns: Curative Pattern (Dominant) vs. Immunization (Emerging)

The Curative Pattern represents the dominant force within the Usage Pattern segment, showcasing a wide range of injectable solutions aimed at treating existing health conditions. This pattern's stronghold in the market is attributed to the increasing prevalence of chronic diseases and the ongoing development of innovative therapies, ensuring its continual relevance. In contrast, the Immunization pattern is emerging as a significant segment, driven by the heightened emphasis on preventive healthcare and global vaccination efforts. This trend is fueled by technological advancements in drug delivery systems, making immunization more efficient and accessible, especially in regions with rising healthcare needs. Together, both segments illustrate the diverse applications of injectable drug delivery, catering to both curative and preventive approaches.

By Site of Delivery: Intramuscular (Largest) vs. Subcutaneous (Fastest-Growing)

The Global Injectable Drug Delivery showcases a diverse distribution across various sites of delivery, with intramuscular (IM) delivery dominating the landscape. This segment's leading position is attributed to its rapid onset of action and the ability to administer larger volumes of medication. Conversely, the subcutaneous (SC) route, although currently smaller in market share, is rapidly gaining traction among healthcare providers due to its convenience and patient compliance features.

Subcutaneous (Emerging) vs. Intradermal (Dominant)

The subcutaneous delivery method is emerging as a pivotal player in The Global Injectable Drug Delivery, primarily because of its ease of administration and the rising trend of self-administration by patients. This method allows medications to be infused into the fatty tissue just below the skin, making it suitable for biologics and other medications. On the other hand, the intradermal delivery method is well-established and regarded for its targeted delivery, particularly in vaccinations and allergy testing. However, this method is less common for larger volumes or systemic treatments, thus solidifying intradermal as a dominant method within specific applications.

Get more detailed insights about Injectable Drug Delivery Devices Market Research Report - Global Forecast To 2035

Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Injectable drug delivery market accounted for USD 8.01 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The rise in biologics sales and the rise in demand for self-injection devices are factors in the prevalence of chronic diseases.

With the increasing cases of chronic diseases, the rise in disposable income, the rising concern for comfort and safety, and the rising number of partnerships in this market, this sector is expected to experience the largest growth. New product development, partnerships, partnerships, expansions, mergers, and acquisitions are the main strategies used by the organisations in the market.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: INJECTABLE DRUG DELIVERY MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Injectable drug delivery market accounts for the second-largest market share. This region now dominates the market for insulin pens in Europe as a result of increasing research and development in this area. The two German businesses, Emperra GmbH E-Health Technologies and Pendiq Intelligent Diabetes Care, respectively, developed and commercialized the insulin pens ESYSTA and Pendiq. Moreover, UK market of Injectable drug delivery held the largest market share, and the Germany market of Injectable drug delivery was the fastest-growing market in the region.

Asia Pacific Injectable drug delivery Market is expected to grow at the fastest CAGR from 2022 to 2030. It is Since more people are becoming aware of these delivery methods, there are more patients, and ready-to-use injectables are replacing traditional drug administration injectables. Further, the China market of Injectable drug delivery held the largest market share, and the India market of Injectable drug delivery was the fastest-growing market in the region.

Key Players and Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of Injectable drug delivery grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the Injectable drug delivery industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the Injectable drug delivery industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Injectable drug delivery industry has provided medicine with some of the most significant benefits. The Injectable drug delivery market major player such as Eisai Co. Ltd, Antares Pharma, AstraZeneca, Becton, Dickinson and Company, Eli Lilly and Company.

With its corporate headquarters in Düsseldorf, Gerresheimer AG is a German manufacturer of packaging materials for medication and drug delivery systems manufactured of special-purpose glass and plastics. The corporation operates production facilities in Asia, the Americas, and Europe. Gerresheimer increased the scope of its collaboration with Taisei Medical Co. Ltd. in 2016 to promote its ClearJect syringes and offer technical support to customers. Additionally, the business intends to expand its line of COP syringes in collaboration with Taisei Medical by producing Gx RTF ClearJect brand syringes that combine ClearJect and its glass RTF (ready-to-fill) idea.

This partnership is intended to assist the company in expanding both its clientele and product line in the syringe needles sector.

An American international healthcare corporation, Baxter International Inc., has its corporate headquarters in Deerfield, Illinois. The company's main areas of concentration include chronic and acute medical disorders, including kidney illness. The leading manufacturer of active pharmaceutical ingredients, ScinoPharm Taiwan, Ltd., and Baxter International Inc. partnered strategically in February 2017. (API). Five injectable medications will need to be developed, produced, and made available for sale as part of this collaboration.

Key Companies in the Injectable Drug Delivery Devices Market market include

Industry Developments

Q2 2024: Becton Dickinson launches new pre-filled syringe platform for biologics Becton Dickinson announced the launch of a new pre-filled syringe platform designed specifically for biologic drugs, aiming to improve drug stability and patient safety.
Q2 2024: West Pharmaceutical Services Announces Opening of New Manufacturing Facility in Singapore West Pharmaceutical Services opened a new manufacturing facility in Singapore to expand its production capacity for injectable drug delivery devices, targeting growth in the Asia-Pacific region.
Q3 2024: Ypsomed and Novo Nordisk enter partnership to develop next-generation autoinjectors Ypsomed and Novo Nordisk announced a partnership to co-develop next-generation autoinjectors for self-administration of biologic therapies.
Q3 2024: Stevanato Group receives FDA clearance for Alba® Connect smart injector Stevanato Group received FDA clearance for its Alba® Connect smart injector, a connected device designed to improve adherence and monitoring for injectable therapies.
Q4 2024: Phillips-Medisize secures contract to supply wearable injectors for major US pharma company Phillips-Medisize announced it has secured a contract to supply wearable injectors to a major US pharmaceutical company for a new biologic drug launch.
Q4 2024: SHL Medical raises $150 million in private funding round to expand autoinjector production SHL Medical completed a $150 million private funding round to expand its autoinjector manufacturing capacity and accelerate development of new delivery platforms.
Q1 2025: Gerresheimer acquires Sensile Medical to strengthen digital drug delivery portfolio Gerresheimer announced the acquisition of Sensile Medical, enhancing its portfolio with digital and connected drug delivery devices for injectable therapies.
Q1 2025: Bespak by Recipharm receives CE mark for new pen injector platform Bespak by Recipharm received CE mark approval for its new pen injector platform, enabling commercial launch in European markets.
Q2 2025: Owen Mumford appoints new CEO to drive global expansion of injectable device business Owen Mumford announced the appointment of a new CEO, tasked with accelerating global expansion and innovation in its injectable drug delivery device segment.
Q2 2025: Nemera opens new R&D center in France for advanced injectable device development Nemera opened a new research and development center in France focused on the design and development of advanced injectable drug delivery devices.
Q2 2025: Vetter Pharma secures multi-year contract with European biotech for fill-finish of injectable biologics Vetter Pharma announced a multi-year contract with a European biotech company to provide fill-finish services for injectable biologic products.
Q3 2025: Credence MedSystems closes $40 million Series C funding to accelerate commercialization of Companion® Syringe System Credence MedSystems closed a $40 million Series C funding round to support the commercialization and global rollout of its Companion® Syringe System for injectable drugs.

Future Outlook

Injectable Drug Delivery Devices Market Future Outlook

The Global Injectable Drug Delivery is projected to grow at a 7.21% CAGR from 2024 to 2035, driven by technological advancements, increasing chronic diseases, and rising demand for self-administration devices.

New opportunities lie in:

Development of smart injectable devices with real-time monitoring capabilities.
Expansion into emerging markets with tailored product offerings.
Partnerships with telehealth platforms for integrated drug delivery solutions.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

Market Segmentation

Injectable Drug Delivery Devices Market Device Outlook

Conventional Injection Devices
Self-Injection Devices

Injectable Drug Delivery Devices Market Usage Pattern Outlook

Curative Pattern
Immunization

Injectable Drug Delivery Devices Market Site of Delivery Outlook

Intramuscular
Subcutaneous
Intradermal

Injectable Drug Delivery Devices Market Therapeutic Application Outlook

Autoimmune Diseases
Hormonal Disorders and Cancer

Report Scope

MARKET SIZE 2024	124.69(USD Billion)
MARKET SIZE 2025	133.68(USD Billion)
MARKET SIZE 2035	268.23(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	7.21% (2024 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Market analysis in progress
Segments Covered	Market segmentation analysis in progress
Key Market Opportunities	Advancements in smart delivery systems enhance patient compliance in The Global Injectable Drug Delivery.
Key Market Dynamics	Technological advancements and regulatory changes drive innovation and competition in the injectable drug delivery market.
Countries Covered	North America, Europe, APAC, South America, MEA